6 News & Press Releases found
Adaptimmune LLC News
-
Translational Data at SITC 2021 from Adaptimmune’s Phase 1 SURPASS Trial Indicate Adding AKTi to Manufacturing May Contribute to Sustained Antitumor Activity of Next-gen SPEAR T-cells
Inhibition of AKT signaling during ex vivo T-cell expansion phase of manufacturing provides further proliferative potential and enhanced memory phenotype of next-gen SPEAR T-cells Data suggests that addition of AKT inhibitor (AKTi) ...
-
Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS
SPEARHEAD-1 trial will meet its primary endpoint and data will be used to support BLA filing for afami-cel next year The overall response rate (ORR) per Independent Review was 34% (36% in patients with synovial sarcoma and 25% for patients with ...
-
Adaptimmune to Present Data Updates at Upcoming CTOS and SITC Meetings
Clinical update and translational data from SPEARHEAD-1 in patients with synovial sarcoma and MRCLS to be presented at CTOS The Company will host its first virtual medical symposium at CTOS Translational data from Phase 1 SURPASS trial to be ...
-
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
Combining both companies’ cell therapy leadership and expertise, the collaboration covers the research and development of “off-the-shelf” cell therapies for up to five shared cancer targets and the development of a novel ...
-
Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit
One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff Data presented today at the International Liver Cancer Association meeting at 12:25 p.m. CET Adaptimmune ...
-
First Preclinical Data from Adaptimmune’s Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model
Preclinical data validate that human T-cells expressing a TCR targeting mesothelin, independent of HLA recognition, can kill human tumor cells HiT works as well, or better than, a TRuC construct targeting mesothelin in preclinical studies ...